Results 91 to 100 of about 106,112 (301)
EFFICACY OF TOCILIZUMAB IN THE TREATMENT OF PATIENTS WITH SEVERE INFECTION [PDF]
, 2022 SIMONA CLAUDIA CAMBREA
openalex +1 more source
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease
Arthritis &Rheumatology, EarlyView.Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman +2 more
wiley +1 more source
Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [PDF]
, 2016 Objectives To summarize and compare the benefits and harms of biological agents used as monotherapy for rheumatoid arthritis (RA) in order to inform decisions for patients who are intolerant to conventional DMARD therapy.
Bliddal, Henning +12 more
core +2 more sources
Arthritis &Rheumatology, EarlyView.Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih +3 more
wiley +1 more source
EClinicalMedicine, 2020 Background: Patients with severe coronavirus disease 2019 (COVID-19) have elevated levels of acute phase reactants and inflammatory cytokines, including interleukin-6, indicative of cytokine release syndrome (CRS).
Antonio Mastroianni +7 more
doaj +1 more source
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales [PDF]
, 2012 Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical ...
Andrew J. K. Ostor +9 more
core +2 more sources
Arthritis &Rheumatology, EarlyView.Objective Giant cell arteritis (GCA) is a large‐vessel vasculitis, potentially causing complications such as blindness and strokes. This study aims to gain insights into the pathogenesis of GCA by identifying specific DNA methylation signatures in the arterial tissue of patients with this vasculitis. Methods DNA methylation profiling was analyzed in 79
Gonzalo Borrego‐Yaniz +18 more
wiley +1 more source
Rheumatology and Therapy, 2018 Introduction This study was conducted to observe patterns of use of the interleukin-6 receptor-alpha inhibitor tocilizumab in routine clinical practice in patients with rheumatoid arthritis (RA).
Boulos Haraoui +5 more
doaj +1 more source
PMS48 Cost-Effectiveness of Tocilizumab for The Management of Inadequately Responding Rheumatoid Arthritis Patients [PDF]
, 2003 Weiner, LawrencePrimer pla de l'obra. Tres grans paral·lelepípedes de formigó, amb aparença de sarcòfags.Repartits al llarg de l'avinguda.
Hansen, R.N. +3 more
core +1 more source